Amylin, Takeda suspend PhII obesity study

Amylin and partner Takeda suspended a Phase II trial of their obesity drug, a combination of diabetes drug pramlintide and analogue hormone metreleptin. The study was halted so that the companies could investigate a new antibody-related laboratory with metreleptin treatment in two patients who participated in a previously completed clinical study of obesity.

"The safety of patients in our clinical programs is of paramount concern to the companies. We have taken this precaution so that we can thoroughly investigate this finding," said Orville Kolterman, M.D., senior vice president and chief medical officer of Amylin Pharmaceuticals. Amylin stressed that the halt won't have any impact on the company's lipodystrophy development program investigating the use of metreleptin to treat diabetes and/or hypertriglyceridemia in patients with rare forms of lipodystrophy.

The announcement is one more piece of bad news for the already beleaguered field of obesity drug development. In the past year the FDA has shot down potential treatments from Orexigen, Vivus and Arena Pharmaceuticals. Safety remains the biggest stumbling block for developers in the field. 

- check out the release
- here's more from the Wall Street Journal

Special Report: Obesity drugs: Where are we now?

Suggested Articles

Denali is partnering with Biogen on its Parkinson's disease program, netting a $560 million upfront fee and a $465 million investment.

In the first half of 2020, the regenerative medicine sector raised $10.7 billion, more than the total it raised in 2019.

The trial linked RG6346 to reductions in hepatitis B surface antigen that suggest the RNAi therapy can hold its own against drugs from J&J and Vir.